XLH

(redirected from X-linked hypophosphatemia)
Also found in: Medical, Wikipedia.
AcronymDefinition
XLHX-linked Hypophosphatemia
XLHX Linked Hydrocephalus (genetic disorder)
XLHX-Linked Hypogammaglobulinaemia (genetic disorder)
XLHHarley-Davidson Sportster motorcycle model
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
"In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets," the authors write.
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.
Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 2016;56:176-185.
X-linked hypophosphatemia and autosomal dominant hypophosphatemia are biochemically indistinguishable from tumor-induced osteomalacia; genetic testing for the PHEX (phosphate-regulating gene with homologies to endopeptidase on the X-chromosome) and FGF23 genes will identify patients with X-linked hypophosphatemia and autosomal dominant hypophosphatemia, respectively (1, 3, 9, 10).
M2 EQUITYBITES-April 18, 2018-The US Food and Drug Administration awards approval for Crysvita for rare inherited form of rickets, x-linked hypophosphatemia
Food and Drug Administration has approved Crysvita for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older.
Food and Drug Administration has approved Crysvita for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older.
Kyowa Hakko Kirin Co, Kyowa Kirin International, and Ultragenyx Pharmaceutical announced that the Committee for Medicinal Products for Human Use, the European Medicines Agency's scientific committee, has adopted a Positive Opinion recommending the conditional marketing authorisation of burosumab, an anti-FGF23 human monoclonal antibody, for the treatment of X-linked hypophosphatemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.
Ultragenyx Pharmaceutical, Kyowa Hakko Kirin, and Kyowa Kirin International announce that the FDA has accepted the Biologics License Application, or BLA, for burosumab to treat pediatric and adult patients with X-Linked Hypophosphatemia, or XLH, and has granted Priority Review status.
Full browser ?